糖皮质激素在55型腺病毒性肺炎辅助治疗中的疗效分析

Efficacy Analysis of Glucocorticoid in Adjuvant Treatment of Type 55 Adenoviral Pneumonia

目的分析糖皮质激素在55型腺病毒性肺炎辅助治疗中的临床疗效,为糖皮质激素应用于55型腺病毒性肺炎提供依据。方法收集2018-02~04月在作者医院科室收治的48例55型腺病毒性肺炎患者资料,以是否应用了糖皮质激素将患者分为观察组(n=24)和对照组(n=24),回顾性分析糖皮质激素对55型腺病毒肺炎的治疗效果。结果55型腺病毒性肺炎患者的一般症状明显改善,但两组患者的发热热程,肺部炎症吸收速率和住院周期间比较差异无统计学意义(P>0.05)。结论糖皮质激素对55型腺病毒肺炎的临床疗效有限,不建议常规使用糖皮质激素治疗55型腺病毒肺炎。

Objective To analyze the clinical efficacy of adjuvant therapy with glucocorticoid for type 55 adenovirus pneumonia,and to provide the basis for the application of glucocorticoid in the treatment of type 55 adenovirus pneumonia.Methods A total of 48 cases of type 55 adenoviral pneumonia patients in author’s hospital from February to April 2018 were collected,the patients were divided into observation group(n=24)and control group(n=24)according to whether glucocorticoid had been used,and the therapeutic effect of glucocorticoid on type 55 adenoviral pneumonia was retrospectively analyzed.Results The general symptoms of patients with type 55 adenoviral pneumonia were improved,but there were no significantly different between the two groups in the patient’s fever duration,lung inflammation absorption and hospitalization period(P>0.05).Conclusion The clinical efficacy of glucocorticoid in the treatment of type 55 adenovirus pneumonia is limited and routine use of glucocorticoids is not recommended.